
Lighting the Way for Improved Detection of Ovarian Cancer
Pafolacianine, an imaging drug that can help surgeons identify ovarian cancer lesions, has recently been accorded FDA approval.
Each year, WCRF designs, funds, conducts, and publishes numerous clinical studies on the spectrum of women’s cancers. All our gynecologic oncology experts work with the belief that each new clinical trial carries the potential to fundamentally change the future of patients with women’s cancers.
Take a look at how WCRF has contributed to the field of gynecologic oncology.